Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Date:8/14/2008

- Company to Host Conference Call at 4:30 p.m. ET Today -

SUNNYVALE, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its fourth quarter and fiscal year ended June 30, 2008. The net loss for the fourth quarter of fiscal 2008 was $4.6 million, or $0.18 per share, compared to a net loss of $7.0 million, or $0.27 per share, for the fourth quarter of fiscal 2007.

Total operating expenses were $4.8 million for the fourth quarter of fiscal 2008 compared to $7.6 million for the fourth quarter of fiscal 2007. Share-based compensation expense was $0.5 million in the fourth quarter of fiscal 2008 compared to $0.8 million in the fourth quarter of fiscal 2007. The decrease in total operating expenses in the fourth quarter of fiscal 2008 was primarily related to reduced personnel expenses due to lower headcount, lower outside clinical trial costs and reduced preclinical expenses associated with the company's Factor VIIa inhibitor program due to the completion of preclinical activities.

Pharmacyclics also reported financial results for the fiscal year ended June 30, 2008. The net loss for the fiscal year ended June 30, 2008 was $24.3 million, or $0.93 per share. This compares to a net loss of $26.2 million, or $1.08 per share, for fiscal year 2007.

As of June 30, 2008, the company had cash, cash equivalents and marketable securities totaling $16.8 million. This compares to $38.8 million in cash, cash equivalents and marketable securities as of June 30, 2007.

Fiscal 2009 Guidance

Pharmacyclics projects total operating expenses, excluding share-based compensation, of between $14 and $15 million for fiscal year 2009, including general and admini
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
2. Pharmacyclics Announces It Received Nasdaq Notification
3. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... DIEGO , April 23, 2015  Neurocrine Biosciences, ... Company will report its first quarter 2015 results before ... Neurocrine will then host a live conference call and webcast ... update Thursday morning, April 30, 2015 at 8:00 a.m. ... can access the live conference call by dialing 866-952-1906 ...
(Date:4/23/2015)... Calif. , April 23, 2015  Veracyte, Inc. (NASDAQ: ... into a definitive agreement to sell approximately $40 million ... the agreement, the investors will purchase an aggregate of ... of $8.15 per share, the closing stock price on ... new and existing investors, including Broadfin Capital, Camber Capital, ...
(Date:4/23/2015)... 23, 2015  Metanome, Inc., an industry leader ... has changed its name to Diversigen, Inc.  The ... the single commercial source for the myriad of ... the diverse opportunities of the microbiome.  From the ... – including those that are difficult to handle, ...
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... Jan. 7 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... a research group led,by Dr. Richard Vile ... in Rochester,Minnesota, published the results of its ... various combinations of reovirus and cyclophosphamide in,vivo. ...
... /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation (KWBT.OB) ... the test results on,Kiwa,s fertilizer products "Pen ... both of,which passed fertilizer sample tests. The ... Amino Acid Leaf Fertilizer,Registration Certificate., In ...
... Jan. 7 DRI Capital (formerly Drug Royalty,Corporation ... investment,strategy and has launched a Structured Finance Fund ... fund is focused on providing,both revenue producing and ... for a variety of uses. The fund represents ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment 2Kiwa Fertilizers Pass Independent Tests 2Kiwa Fertilizers Pass Independent Tests 3DRI Capital Launches Structured Finance Fund 2
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... frozen in place frozen solid All of these phrases have ... truth about this southerly point on the globe. Although the ... the most extreme cold on the planet, this ecosystem is dynamic, ... A report published in the March issue of Ecology argues ...
... When scientists around the world think of dung, they think ... University, is one of the world,s foremost authorities on animal ... "You have got to laugh at this bizarre resource," says ... don,t think anyone is keeping track, I suspect we have ...
... a slow-moving mass of cold water that travels south along ... seeing increasing areas of water off Washington and Oregon with ... marine animals that cannot leave the low-oxygen areas. Were ... and far more intense than what has been recorded in ...
Cached Biology News:Antarctic life hung by a thread during ice ages 2Antarctic life hung by a thread during ice ages 3Dung happens and helps scientists 2Dung happens and helps scientists 3Oregon researchers study widespread areas of low oxygen off northwest coast 2
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
... antibody development to targets including proteins and ... and cancer-specific surface antigens. A&Gs service ... completed in approximately 40 days (duration may ... antigens). Phase I: Immunization, test bleed ...
... ZMD.368. Immunogen: Synthetic peptide derived ... human WNT2B/WNT13 protein. Specificity: Specific ... and rat WNT2B/WNT13 proteins. Recognizes both ... Reactivity: Mouse Human Rat (positive controls: ...
... Immunogen: Synthetic peptide derived from the ... (chromosome 17 open reading frame 37 (C17orf37 ... the C35 protein. On Western blots it ... band. Reactivity: Human (positive control: full-length ...
Biology Products: